Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04575584 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)
A Phase 2 study, sponsored by Merck Sharp & Dohme.
- Terminated
- Registry status
- Phase 2
- Development phase
- 304
- Enrollment target
NCT04575584 is a Phase 2 study that was terminated before completion, run by Merck Sharp & Dohme. The registered enrollment target is 304 participants.
The verdict
NCT04575584, a Phase 2 study, was terminated before completion, sponsored by Merck Sharp & Dohme.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 304 participants
- Enrollment target
Study Summary
This study aims to evaluate the safety, tolerability and efficacy of molnupiravir (MK-4482) compared to placebo. The primary hypothesis is that molnupiravir is superior to placebo as assessed by the rate of sustained recovery through Day 29.
Interventions
- DRUG Placebo
- DRUG Molnupiravir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 304 participants |
| Start Date | 2020-10-19 |
| Est. Completion | 2021-08-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04575584
The ClinicalTrials.gov registry entry for NCT04575584 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 304 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04575584 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04575584 about?
NCT04575584 is a clinical study titled "Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)". This study aims to evaluate the safety, tolerability and efficacy of molnupiravir (MK-4482) compared to placebo. The primary hypothesis is that molnupiravir is superior to placebo as assessed by the rate of sustained recovery through Day 29.
What is the current status of trial NCT04575584?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 304 participants. The study started on 2020-10-19. Estimated completion is 2021-08-11.
What interventions are being tested in trial NCT04575584?
The interventions under investigation include: Placebo (DRUG), Molnupiravir (DRUG).
Who is sponsoring clinical trial NCT04575584?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.